Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
0
Story being shared
NovImmune's orphan drug candidate wins $7.8M grant
A consortium of European researchers received a grant worth about $7.8 million from the European Commission to fund clinical studies of NovImmune's NI-0501, an anti-IFNγ monoclonal antibody, for the treatment of hemophagocytic lymphohistiocytosis, an orphan disease that affects mainly children. The consortium, led by NovImmune, includes Lonza Biologics and two children's hospitals in Italy.
Or we can send an email on your behalf